Cardinal Health on Tuesday forecast fiscal 2027 adjusted earnings well above Wall Street estimates, citing sustained demand for specialty and branded medicines that treat complex, chronic conditions.
Stronger profits driven by specialty medicines
The Dublin, Ohio-based distributor said it expects adjusted earnings per share for fiscal 2027 of $12.40 to $12.60, above analysts' consensus of $12.04. The company also reported a fourth-quarter adjusted profit of $2.91 per share, beating average estimates of $2.42.
Cardinal's total revenue for the quarter was $63.67 billion, a 6 per cent increase year over year, although that figure fell short of aggregate analyst forecasts of $65.03 billion. The company's largest operating unit, Pharmaceutical and Specialty Solutions, saw sales rise 6 per cent to $55.4 billion during the quarter, a sign that higher-margin specialty medicines and branded therapies are supporting results.
Context and implications for health-care supply chains
Drug distributors such as Cardinal Health are increasingly benefitting from rising uptake of biosimilars and specialty pharmaceuticals used to treat conditions including cancer, rheumatoid arthritis and other autoimmune diseases. Those medicines often command higher prices and narrower distribution channels than traditional generics, affecting margins and inventory strategies across the supply chain.
- Cardinal forecasts $12.40–$12.60 adjusted EPS for fiscal 2027.
- Fourth-quarter revenue was $63.67 billion, up 6 per cent year over year.
- Pharmaceutical and Specialty Solutions sales rose to $55.4 billion.
In recent months the company has moved to expand its exposure to home-care and chronic-disease supplies by acquiring businesses that broaden its direct-to-consumer platforms. Last month, Cardinal completed two tuck-in acquisitions — the diabetes supplies business from AdaptHealth and medical-supply provider Strive Medical — for about $360 million combined. Executives say those additions strengthen access to products such as continuous glucose monitors and urology supplies.
| Metric | Reported | Analysts' average |
|---|---|---|
| Adjusted EPS (Q4) | $2.91 | $2.42 |
| Total revenue (Q4) | $63.67 billion | $65.03 billion |
| FY2027 adjusted EPS guidance | $12.40–$12.60 | $12.04 |
Share repurchases and investor returns
Cardinal also signalled a return of capital to shareholders, indicating plans for $1 billion in share repurchases during fiscal 2027. The buyback programme, together with acquisitions aimed at expanding home-care distribution, points to a strategy balancing growth investments with efforts to boost shareholder value.
Industry analysts have noted that distribution firms stand to gain as health systems and patients increasingly rely on specialty therapies and home-based care models. For health-care providers and payers, that trend can complicate procurement and budgeting, given the higher unit costs and complex handling these products sometimes require.
While Cardinal’s revenue figure missed the consensus, the stronger-than-expected profit and upbeat guidance suggest that higher-margin products are compensating for other pressures. The company’s results and outlook will be watched closely by investors and health-sector stakeholders seeking signs of how evolving demand for advanced therapies will shape supply chains and costs going forward.
Reporting by Reuters contributed to this article.
